…
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Larimar Therapeutics Inc is a NASDAQ-listed biopharmaceutical company that, according to public disclosures, develops novel therapeutic programs. Long-term growth drivers may include progress in its clinical pipeline, licensing or partnership deals, and successful commercialization, which could support upside tied to program milestones.
Material investment risks include clinical trial setbacks, regulatory delays, high cash burn with likely financing needs, limited operating history and intense competition in specialty therapeutics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
| Net income | -165.67M | -80.60M | -36.95M | -34.18M | -50.31M |
| Selling general administrative | 18.27M | 17.61M | 14.09M | 12.28M | 12.07M |
| Selling and marketing expenses | - | - | 14.07M | - | - |
| Gross profit | -0.35M | -0.32M | -0.31M | - | - |
| Reconciled depreciation | 0.35M | 0.32M | 0.31M | 0.32M | 0.33M |
| Ebit | -165.67M | -80.60M | -36.95M | -36.84M | -50.79M |
| Ebitda | -165.32M | -80.29M | -36.64M | -36.53M | -50.47M |
| Depreciation and amortization | 0.35M | 0.32M | 0.31M | 0.32M | 0.33M |
| Non operating income net other | - | - | - | 1.17M | - |
| Operating income | -172.50M | -90.89M | -41.76M | -36.53M | -50.47M |
| Other operating expenses | 172.50M | 90.89M | 41.76M | 36.53M | 50.47M |
| Interest expense | - | - | - | -0.32M | 0.33M |
| Income tax expense | - | - | - | -1.17M | -0.33M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 172.50M | 90.89M | 41.76M | 36.53M | 50.47M |
| Cost of revenue | 0.35M | 0.32M | 0.31M | - | - |
| Total other income expense net | 6.82M | 10.29M | 4.81M | 1.17M | -0.17M |
| Net income from continuing ops | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
| Net income applicable to common shares | - | - | - | -35.35M | -50.64M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M |
| Other current assets | 4.42M | 10.80M | 3.38M | 2.31M | 2.11M |
| Total liab | 67.76M | 28.41M | 14.21M | 15.50M | 14.25M |
| Total stockholder equity | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M |
| Other current liab | 58.47M | 20.87M | 7.39M | 8.41M | 6.59M |
| Common stock | 0.08M | 0.06M | 0.04M | 0.04M | 0.02M |
| Capital stock | 0.08M | 0.06M | 0.04M | 0.04M | 0.02M |
| Retained earnings | -434.83M | -269.16M | -188.55M | -151.60M | -116.25M |
| Other assets | - | - | - | 1.98M | 2.01M |
| Cash | 85.41M | 33.22M | 26.75M | 26.82M | 70.10M |
| Total current liabilities | 64.80M | 24.36M | 9.51M | 10.71M | 8.85M |
| Net debt | -81.34M | -28.10M | -21.20M | -21.42M | -64.09M |
| Short term debt | 1.10M | 1.06M | 0.84M | 0.61M | 0.59M |
| Short long term debt total | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Other stockholder equity | 512.78M | 440.76M | 270.15M | 262.50M | 180.65M |
| Property plant equipment | - | - | - | 0.83M | 4.46M |
| Total current assets | 142.02M | 195.30M | 90.17M | 120.74M | 72.20M |
| Net tangible assets | - | - | - | 110.90M | 64.41M |
| Short term investments | 51.44M | 150.24M | 60.04M | 91.60M | 0.00M |
| Net receivables | 0.75M | 1.05M | - | - | 0.21M |
| Inventory | - | - | - | - | -0.21M |
| Accounts payable | 5.22M | 2.42M | 1.28M | 1.69M | 1.66M |
| Accumulated other comprehensive income | 0.05M | 0.15M | 0.08M | -0.03M | - |
| Common stock total equity | - | - | - | 0.04M | - |
| Retained earnings total equity | - | - | - | -151.60M | - |
| Non currrent assets other | 1.13M | 1.20M | 0.66M | 1.98M | 2.01M |
| Non current assets total | 3.82M | 4.92M | 5.76M | 5.67M | 6.46M |
| Capital lease obligations | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 100.40M | -85.39M | 33.35M | -90.86M | 24.50M |
| Change to liabilities | - | - | - | 1.84M | -0.97M |
| Total cashflows from investing activities | 100.31M | -85.39M | 33.35M | -90.96M | 24.17M |
| Total cash from financing activities | 65.09M | 161.88M | 0.03M | 75.26M | 19.89M |
| Change to operating activities | - | - | - | 1.64M | 3.72M |
| Net income | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
| Change in cash | 52.19M | 5.74M | -0.08M | -43.27M | 1.95M |
| Begin period cash flow | 33.82M | 28.09M | 26.82M | 71.44M | 69.49M |
| End period cash flow | 86.02M | 33.82M | 26.75M | 28.16M | 71.44M |
| Total cash from operating activities | -113.20M | -70.76M | -33.46M | -27.57M | -42.10M |
| Issuance of capital stock | 65.09M | 161.81M | 0.00M | 75.26M | 19.89M |
| Depreciation | 0.35M | 0.32M | 0.31M | 0.32M | 0.33M |
| Other cashflows from investing activities | - | - | 0.03M | - | - |
| Sale purchase of stock | - | - | - | 75.26M | - |
| Other cashflows from financing activities | 65.09M | 0.08M | 0.03M | -90.96M | 24.17M |
| Change to netincome | - | - | - | 6.62M | 5.46M |
| Capital expenditures | 0.09M | 0.52M | 0.16M | 0.10M | 0.33M |
| Cash flows other operating | - | - | - | -0.22M | - |
| Cash and cash equivalents changes | - | - | - | -43.27M | - |
| Change in working capital | 47.10M | 6.17M | -2.51M | 1.67M | 2.75M |
| Stock based compensation | 7.00M | 8.80M | 7.62M | 6.62M | 5.47M |
| Other non cash items | -1.98M | -5.45M | -1.93M | -0.82M | -0.01M |
| Free cash flow | -113.29M | -71.28M | -33.62M | -27.67M | -42.44M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics Inc |
0.01 0.50% |
3.02 | - | - | - | 3.08 | -4.13 |
| NVO Novo Nordisk A/S |
-0.99 2.39% |
40.60 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.90 0.73% |
533.89 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
5.36 0.56% |
957.76 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004
844 511 9056
71
| Name | Title | Year Born |
|---|---|---|
| Dr. Carole S. Ben-Maimon M.D. | CEO, Pres & Director | 1959 |
| Mr. Michael Celano CPA | Sec. & CFO | 1959 |
| Mr. John Berman | VP of Fin. & Operations | NA |
| Ms. Jennifer Spokes Johansson | VP of Regulatory Affairs & Counsel | NA |
| Dr. Nancy M. Ruiz | Chief Medical Officer | NA |
| Mr. Francis Michael Conway | VP & Controller | NA |
| Dr. Carole S. Ben-Maimon M.D. | CEO, President & Director | 1959 |
| Mr. Michael Celano CPA | Secretary & CFO | 1959 |
| Mr. John Berman | Vice President of Finance & Administration | NA |
| Ms. Jennifer Spokes Johansson | Vice President of Legal & Compliance | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.